Evidence map›Paper›PMID 33058262›Full record

ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2020

Identification and characterization of functional long noncoding RNAs in cancer.

Christiane E Olivero, Nadya Dimitrova

Open access · bronzeAbstract readReview
In one paragraph

Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Recent Advances in Cancer Immunotherapy Aided by Regulatory Non-Coding RNA: A Review.Asian Pacific journal of cancer prevention : APJCP · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Overexpression ofScience immunology · 2024
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. A mechanistic view of long noncoding RNAs in cancer.Wiley interdisciplinary reviews. RNA · 2022
    Review
  15. Article
  16. Identification and characterization of functional long noncoding RNAs in cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Christiane E OliveroDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
Nadya DimitrovaDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
Yale University · US

Funding

Roles and mechanisms of cis-regulatory IncRNAs in the p53 tumor suppressor pathwayR37CA230580 · NCI · YALE UNIVERSITY · PI DIMITROVA, NADYA M · 2018 to 2024
$2.5M
NCI NIH HHS R37 CA230580
6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) have emerged as key regulators in a variety of cellular processes that influence disease states. In particular, many lncRNAs are genetically or epigenetically deregulated in cancer. However, whether lncRNA alterations are passengers acquired during cancer progression or can act as tumorigenic drivers is a topic of ongoing investigation. In this review, we examine the current methodologies underlying the identification of cancer-associated lncRNAs and highlight important considerations for evaluating their biological significance as cancer drivers.

Indexed as

AnimalsCarcinogenesisEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansNeoplasmsRNA, Long NoncodingRNA, Long NoncodingcancerfunctionGEMMsidentificationlncRNA

Identifiers

PMID33058262
PMCPMC7756267
OpenAlexW3092849998

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.